Premium
The use of a tumor colony assay in predicting chemotherapeutic drug response in murine bladder cancer
Author(s) -
Niell Harvey B.,
Soloway Mark S.,
Wood Charles A.,
McCallum Lee W.,
Webster Kim
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830815)52:4<619::aid-cncr2820520408>3.0.co;2-9
Subject(s) - medicine , drug , bladder cancer , predictive value , in vitro , drug response , cancer , chemotherapy , pharmacology , cancer research , oncology , biology , biochemistry
A tumor colony assay (TCA) was evaluated for its ability to predict anticancer drug responses in an N‐[4‐(5‐nitro‐2‐furyl)‐2‐thiazolyl]‐formamide (FANFT)‐induced murine bladder tumor (MBT) model. Ten anticancer drugs were evaluated in vitro and in vitro using four MBT cell lines (40 drug responses). Using the optimum criteria for drug response, the TCA accurately predicted drug responses in the murine model 65% of the time with a true‐positive predictive rate of 54% and a true‐negative predictive rate of 70%. Drug testing tumor cells immediately on removal from the mouse resulted in a true‐positive predictive rate of 77% and a true‐negative predictive rate of 100%. The authors conclude that the TCA can predict response to chemotherapy in the MBT model and may be useful in screening investigation compounds for the subsequent evaluation in this murine bladder tumor model.